Food and Drug Administration Safety and Innovation Act

From Wikipedia, the free encyclopedia
Jump to: navigation, search

The Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA) is a piece of American regulatory legislation signed into law on July 9, 2012. It gives the United States Food and Drug Administration the authority to collect user fees from the medical industry to fund reviews of innovator drugs, medical devices, generic drugs and biosimilar biologics. It also reauthorizes two programs that encourage pediatric drug development.

The law also contains the Synthetic Drug Abuse Prevention Act of 2012. The legislation bans synthetic compounds commonly found in synthetic marijuana ("K2"[1] or "Spice"), synthetic stimulants ("bath salts"[2]), and hallucinogens, by placing them under Schedule I of the Controlled Substances Act.


  1. ^ Vashi, Sonam (September 26, 2012). K2 Trend Not Slowing Down WebMD Medical News via KOKI-TV
  2. ^ Marder, Jenny (September 20, 2012). Bath Salts: The Drug That Never Lets Go. PBS NewsHour

External links[edit]